YAP1 and malignant colon neoplasm: In Wnt-activated colon cancer cells, targeting of YES1 with the approved compound dasatinib inhibits tyrosine phosphorylation of YAP and activation of a β-catenin-YAP1-TBX5 transcriptional complex (Rosenbluh et al., 2012), while in mammary cells inhibition of PI3K/PDK1 was able to restrain the binding of PDK1 to SAV1, resulting disinhibition of upstream Hippo signaling, and reduction of YAP activity (Fan et al., 2013).